Drug-induced Torsades de Pointes (TdP) arrhythmia is of major interest in predictive toxicology. Drugs which cause TdP block the hERG cardiac potassium channel. However, not all drugs that block hERG cause TdP. As such, further understanding of the mechanistic route to TdP is needed. Early afterdepolarisations (EADs) are a cell-level phenomenon in which the membrane of a cardiac cell depolarises a second time before repolarisation, and EADs are seen in hearts during TdP. Therefore, we propose a method of predicting TdP using induced EADs combined with multiple ion channel block in simulations using biophysically-based mathematical models of human ventricular cell electrophysiology. EADs were induced in cardiac action potential models using interventions based on diseases that are known to cause EADs, including: increasing the conduction of the L-type calcium channel, decreasing the conduction of the hERG channel, and shifting the inactivation curve of the fast sodium channel. The threshold of intervention that was required to cause an EAD was used to classify drugs into clinical risk categories. The metric that used L-type calcium induced EADs was the most accurate of the EAD metrics at classifying drugs into the correct risk categories, and increased in accuracy when combined with action potential duration measurements. The EAD metrics were all more accurate than hERG block alone, but not as predictive as simpler measures such as simulated action potential duration. This may be because different routes to EADs represent risk well for different patient subgroups, something that is difficult to assess at present.
Since these discoveries, testing for hERG block has become a mandatory requirement for new phar-
Methods
We selected 41 drugs of known torsadogenic risk, and simulated their ion channel blocking effects in 89 the O'Hara 2011 human ventricular cell model. [43] Using a range of interventions, we determined the 90 threshold of intervention at which an EAD could be provoked in the cell model, i.e. the lowest level 91 of intervention that was necessary for an EAD to be produced. The differences in 'threshold for EAD' 92 between different drugs were used to classify drugs by arrhythmic risk. These steps are detailed below. 93 Drug inclusion criteria 94 To select drugs to use as a training set, we used three criteria based on the amount of data available 95 on both the pro-arrhythmic risk of the compound and its effect on ion currents in cardiac cells. 96 1. As a starting point, we included drugs that we previously studied in Mirams et al. [35] . 97 2. Additional drugs were then included in our study if they had been included in five or more of the 98 papers analysing TdP risk discussed in a recent summary paper, [44] and if over 70% of studies 99 agreed on high or low TdP risk. 100 3. Drugs that are on the CiPA list [42] were automatically included if ion current block data were 101 available for three or more channels of interest (even if they had been in fewer than five studies or 102 had poor agreement in risk category between studies). 103 If there was disagreement in risk class using the above sources, the default category was the one used 
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To be included in our dataset, the drugs were also required to have IC 50 values available in the 106 literature for three or more of the ionic currents of interest, found by manual patch clamp. The ionic 107 currents of interest were: the fast and late/persistent sodium currents, the L-type calcium current, 108 the rapid and slow delayed rectifier potassium currents, the transient outward current, and the inward Table 1 : pIC 50 values for each compound in the dataset (shown as log M) for the fast sodium (I Na ), L-type calcium (I CaL ), rapid delayed rectifier potassium (hERG or I Kr ), slow delayed rectifier potassium (I Ks ), persistent sodium (I pNa ), transient outward (I to ) and inward rectifier potassium (I K1 ) currents, and effective free therapeutic plasma concentration (EFTPC) (nM). For references, please see the Supplementary Material. 'n/a' indicates that the channel has been screened and no effect was measured: either the IC 50 value was above the maximum concentration being tested, or there is no drug-induced block of this channel. modelled as a reduction in channel conductance as a function of the concentration of the compound,
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[D], and the IC 50 value. [50] The change in maximum conductance for a channel j was described by a 123 Hill equation:
where g j is the maximum conductance of the drug-blocked channel, andḡ j is the conductance of the 125 channel when there is no compound present. The Hill coefficient here is set to 1, as the variability 126 in experimentally-inferred Hill coefficients from patch clamp can be so high that using 1 as the Hill 127 coefficient may reduce error [51] . Note that this formula was applied for all channel/drug combinations 128 listed in Table 1 , apart from late/persistent sodium in the Grandi model -as this model does not have Table 2 : Mean absolute errors in classification, calculated using Equation 3. The "5 LDA" and "5 SVM" rows are the results from the 5-group cross-validation of linear discriminant analysis classification and support vector machines classification, respectively. The "1 LDA" and "1 SVM" rows are the results from leave-one-out cross-validation. The appearance of early afterdepolarisations (EADs) in a simulation was determined by the slope 135 of the voltage trace between adjacent time points. Whenever the slope was greater than +1 mVms −1 , 
Provoking afterdepolarisations 142
The failure of hERG block alone to predict torsadogenic risk suggests that drug-induced TdP is 143 mediated by more than one ionic mechanism. We hypothesise that the interaction of certain disease 144 states with torsadogenic drugs could lead to greater susceptibility to TdP. We propose to look at the Reset cell model to earlier state.
6:
Set intervention to (α + β) ÷ 2 (e.g. multiply I CaL conductance by this factor).
7:
Run model for 12 s.
8:
Check for Early afterdepolarisation (upwards trajectory after initial depolarisation).
9:
Adjust α or β using interval bisection. This method allows for the grouping of drugs by similarity rather than by rigid categories, allowing 207 for new compounds to be visually ranked by closeness to torsadogenic and non-torsadogenic drugs. The 208 output of the optimal leaf ordering algorithm was evaluated by the sum of the square difference between 209 the risk category of each drug in the ranking and an optimal ordering (2,2,. . . ,2,3,3,. . . ,3,4,4,. . . etc.):
where o is the optimal ordering of risk category, a is the actual risk category, and N is the number of 211 drugs in the dataset. 
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• Category 3: drugs with a measurable incidence or numerous reports of TdP in humans.
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• Category 4: drugs with isolated reports of TdP in humans.
• Category 5: drugs with no reports of TdP in humans. 220 We also considered a binary classifiers, where Categories 2 and 3 were grouped as torsadogenic and 221 Categories 4 and 5 were grouped as non-torsadogenic. Results from this were not materially different, 222 and can be found in the supplementary spreadsheet under "Binary". 223 We used EAD thresholds, APDs, diastolic calcium concentration, and hERG IC 50 /EFTPC max to 224 classify compounds into one of the four TdP risk categories described earlier. We tested two classification 225 methods: linear discriminant analysis (LDA), and support vector machines (SVM).
226
Leave-one-out cross-validation and five-group cross-validation were used to check the robustness and 227 accuracy of both the classifiers. We evaluated performance by calculating the errors in classification 228 (how many risk classes away from the correct class a drug was classified as), and comparing these means 229 of absolute error, E:
where, a is the actual category (i.e. the real risk category for the drug), c is the category assigned using 231 the classification method, and N is the number of drugs in the dataset.
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In LDA, the metrics in categories are assumed to follow a Normal distribution, and the points where 233 the inferred distributions overlap are used as the category boundaries.
[60] In SVM, a hyperplane is used 234 to separate the data points, and the optimal hyperplane is found by maximising the distance between g CaL × 25
g CaL × 28 Figure 3 : Some examples of EADs provoked using the L-type calcium increase protocol, as described in the methods section. The first EAD caused by the increasing intervention for each drug is highlighted in red. The less torsadogenic drug (nitrendipine) requires more provocation than the control to cause an EAD (i.e. its EAD threshold is higher), and the more torsadogenic drug (cisapride) requires less provocation (i.e. its EAD threshold is lower).
Thioridazine needed no hERG block to cause an EAD, despite being a strong I CaL blocker. This is probably due to thioridazine's very strong effect on hERG, with an IC 50 value of 0.034×EFTPC max . with LQT2 or other hERG mutations, drugs which block I CaL could be beneficial in preventing TdP.
ICaL EADs
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I CaL EAD thresholds were lower for drugs which strongly block both the I Na and hERG channels. 
